Procter & Gamble vs Philip Morris International
Procter & Gamble and Philip Morris International are compared on this page to illuminate differences in business models, financial performance, and market context. The analysis stays neutral and accessible, outlining core strategies, revenue drivers, risk factors, and competitive positioning to help readers form an informed view. Educational content, not financial advice.
Procter & Gamble and Philip Morris International are compared on this page to illuminate differences in business models, financial performance, and market context. The analysis stays neutral and acces...
Why It's Moving
Procter & Gamble gains analyst support as earnings beat and valuation appeal spark price target hikes across the street
- UBS lifted its price target to $170 from $161, maintaining a Buy rating, citing favorable SG&A performance and confidence in organic growth drivers for the second half of the year, while noting P&G's valuation sits below its 2-year and 5-year historical averages
- Wells Fargo and BofA Securities also raised targets to $165 and $171 respectively, with the consensus analyst target now standing at $167.67, though investor skepticism persists around the sustainability of recent U.S. category improvements and market share gains
- Insider selling activity—including substantial share disposals by CEO Gary Coombe and Chairman Jon Moeller totaling over $51 million in mid-February—contrasts with the bullish analyst sentiment and may signal mixed conviction about near-term momentum
Philip Morris faces institutional selling pressure and valuation concerns as analysts flag downside risks
- Institutional investors trimmed positions significantly, with First Eagle Investment Management reducing its stake by 14.2% and Boston Partners decreasing holdings, signaling reduced confidence in the stock's near-term trajectory
- Competitive pressures intensified from rivals like British American Tobacco and Japan Tobacco in key growth markets including U.S. nicotine pouches and heated tobacco products, threatening PM's market share expansion plans
- Regulatory risks loom large with potential for new governmental restrictions on tobacco and nicotine products globally, including possible excise tax increases or product bans that could materially impact financial performance
Procter & Gamble gains analyst support as earnings beat and valuation appeal spark price target hikes across the street
- UBS lifted its price target to $170 from $161, maintaining a Buy rating, citing favorable SG&A performance and confidence in organic growth drivers for the second half of the year, while noting P&G's valuation sits below its 2-year and 5-year historical averages
- Wells Fargo and BofA Securities also raised targets to $165 and $171 respectively, with the consensus analyst target now standing at $167.67, though investor skepticism persists around the sustainability of recent U.S. category improvements and market share gains
- Insider selling activity—including substantial share disposals by CEO Gary Coombe and Chairman Jon Moeller totaling over $51 million in mid-February—contrasts with the bullish analyst sentiment and may signal mixed conviction about near-term momentum
Philip Morris faces institutional selling pressure and valuation concerns as analysts flag downside risks
- Institutional investors trimmed positions significantly, with First Eagle Investment Management reducing its stake by 14.2% and Boston Partners decreasing holdings, signaling reduced confidence in the stock's near-term trajectory
- Competitive pressures intensified from rivals like British American Tobacco and Japan Tobacco in key growth markets including U.S. nicotine pouches and heated tobacco products, threatening PM's market share expansion plans
- Regulatory risks loom large with potential for new governmental restrictions on tobacco and nicotine products globally, including possible excise tax increases or product bans that could materially impact financial performance
Investment Analysis
Pros
- Procter & Gamble has a strong analyst consensus with a 'Buy' rating and an average price target suggesting nearly 20% upside over the next year.
- The company maintains a consistent record of dividend payments, making it attractive for income-focused investors seeking steady returns.
- Procter & Gamble operates globally with a diversified portfolio across multiple consumer product segments, supporting stable revenue streams.
Considerations
- Recent insider selling has been notable, potentially indicating concerns about future company performance among key executives.
- The current price-to-earnings ratio is relatively high, which may suggest the stock is overvalued relative to its earnings potential.
- Stock price volatility and bearish near-term sentiment create some uncertainty, with a trading range and recent lower analyst price targets indicating caution.
Pros
- Philip Morris International has shown strong market cap growth of over 27% in the past year, reflecting robust investor confidence and value creation.
- The company is actively transitioning its product portfolio towards smoke-free alternatives, aligning with evolving regulatory and consumer trends.
- Philip Morris ranks highly in several key performance and risk metrics compared to peers in the tobacco and consumer sectors.
Considerations
- Dependence on tobacco products exposes the company to regulatory risks and shifting public health policies impacting long-term growth.
- Stock price has experienced downward movement recently with some analyst caution, reflecting uncertainties in execution of portfolio transformation.
- The company's cyclicality and exposure to commodity pricing fluctuations could impact profitability under adverse market conditions.
Related Market Insights
The Recession-Proof Portfolio: Why These Stocks Thrive When Markets Crumble
Discover recession-proof stocks that thrive in economic downturns. Build a stable, defensive portfolio with essential goods companies. Invest with Nemo's curated Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
Related Market Insights
The Recession-Proof Portfolio: Why These Stocks Thrive When Markets Crumble
Discover recession-proof stocks that thrive in economic downturns. Build a stable, defensive portfolio with essential goods companies. Invest with Nemo's curated Neme.
Aimee Silverwood | Financial Analyst
July 25, 2025
Procter & Gamble (PG) Next Earnings Date
Procter & Gamble is expected to release its next earnings report on April 24, 2026 before market open, covering the third quarter of fiscal year 2026. This follows the company's recent Q2 FY2026 earnings release on January 22, 2026, which reported core EPS of $1.88 in line with prior year and organic sales growth of 0%. The upcoming report will provide investors with updated performance metrics and management guidance for the remainder of the fiscal year.
Philip Morris International (PM) Next Earnings Date
Philip Morris International is scheduled to release its next earnings report on April 22, 2026 before market open, covering Q1 2026 results. Analysts are projecting earnings per share of $1.83 for the quarter. This will be the company's first earnings announcement following its Q4 2025 report released on February 6, 2026, when PM exceeded expectations with an EPS of $1.70 versus the consensus estimate of $1.69.
Procter & Gamble (PG) Next Earnings Date
Procter & Gamble is expected to release its next earnings report on April 24, 2026 before market open, covering the third quarter of fiscal year 2026. This follows the company's recent Q2 FY2026 earnings release on January 22, 2026, which reported core EPS of $1.88 in line with prior year and organic sales growth of 0%. The upcoming report will provide investors with updated performance metrics and management guidance for the remainder of the fiscal year.
Philip Morris International (PM) Next Earnings Date
Philip Morris International is scheduled to release its next earnings report on April 22, 2026 before market open, covering Q1 2026 results. Analysts are projecting earnings per share of $1.83 for the quarter. This will be the company's first earnings announcement following its Q4 2025 report released on February 6, 2026, when PM exceeded expectations with an EPS of $1.70 versus the consensus estimate of $1.69.
Which Baskets Do They Appear In?
Top Stocks for Recessions
These carefully selected stocks have shown remarkable resilience during economic downturns. Our team of professional analysts has identified companies that maintain stability when markets get shaky, giving you options for weathering financial storms.
Published: May 3, 2025
Explore BasketWhich Baskets Do They Appear In?
Top Stocks for Recessions
These carefully selected stocks have shown remarkable resilience during economic downturns. Our team of professional analysts has identified companies that maintain stability when markets get shaky, giving you options for weathering financial storms.
Published: May 3, 2025
Explore BasketBuy PG or PM in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Comparisons
Procter & Gamble vs British American Tobacco
Procter & Gamble vs British American Tobacco compares business models, financials and market context to help readers decide which company to research further.
Procter & Gamble vs Honeywell
A factual, neutral comparison of Procter & Gamble and Honeywell examining business models, financial metrics, and market context to help readers decide what to research next.
Procter & Gamble vs General Electric
Procter & Gamble vs General Electric compares business models, financial performance, and market context in a neutral overview, highlighting similarities, differences, and research factors.